Dabigatran for Treatment and Secondary Prevention of Venous Thromboembolism in Pediatric Congenital Heart Disease
Open Access
- 20 February 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (4) , e028957
Abstract
Background: Congenital heart disease (CHD) is common in children and associated with greater risk of thrombotic complications. Management of these complications with standard‐of‐care treatment is suboptimal for these children. Methods and Results: The effectiveness and safety of dabigatran were demonstrated in pivotal pediatric studies for the treatment of acute venous thromboembolism (VTE; NCT01895777) and secondary VTE prevention (NCT02197416). We report safety and efficacy outcomes from subgroup analyses of these studies for children with CHD (diagnosed according to local practice) and those without. In NCT01895777, 17/21 (81.0%) and 16/27 (59.3%) patients with CHD (including cyanotic) treated with dabigatran and standard of care, respectively, met the primary end point (complete thrombus resolution, freedom from recurrent VTE, and freedom from VTE‐related death; odds ratio [OR], 0.34 [95% CI, 0.08–1.23]). In patients without CHD, 41.0% (n=64) versus 34.9% (n=22) achieved this end point with the respective treatments (OR, 0.77 [95% CI, 0.42–1.41]). Although numerical differences were observed, no heterogeneity in treatment effect of dabigatran on the composite primary end point was detected in patients with and without CHD (interaction P =0.2674). In NCT02197416, recurrent VTE at 12 months occurred in 0/17 patients with CHD versus 3/194 (1.5%) without. No patient with CHD experienced major or clinically relevant nonmajor bleeding events. Conclusions: Data on favorable anticoagulant alternatives for the unmet needs of children with CHD are emerging, and our exploratory results suggest that dabigatran could be an appropriate treatment choice, although challenging sample size limitations in pediatric studies require cautious interpretation of findings. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT01895777, NCT02197416.Keywords
This publication has 40 references indexed in Scilit:
- Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac DiseaseJACC, 2022
- Cerebral Sinus Venous Thrombosis in Infants after Surgery for Congenital Heart DiseaseThe Journal of Pediatrics, 2022
- Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous ThromboembolismJAMA, 2022
- Central Venous Catheter-Related Deep Vein Thrombosis in the Pediatric Cardiac Intensive Care UnitJournal of Surgical Research, 2019
- Management and Outcomes of Patients with Occlusive Thrombosis after Pediatric Cardiac SurgeryThe Journal of Pediatrics, 2015
- Hospital-Associated Venous Thromboembolism in Children: Incidence and Clinical CharacteristicsThe Journal of Pediatrics, 2014
- Warfarin Anticoagulation After Congenital Heart Surgery at a Large Children’s HospitalPediatric Cardiology, 2012
- A Multicenter, Randomized Trial Comparing Heparin/Warfarin and Acetylsalicylic Acid as Primary Thromboprophylaxis for 2 Years After the Fontan Procedure in ChildrenJACC, 2011
- Perioperative Stroke in Infants Undergoing Open Heart Operations for Congenital Heart DiseaseThe Annals of Thoracic Surgery, 2009
- Evaluation of the Coagulation System in Children with Two-Ventricle Congenital Heart DiseaseThe Annals of Thoracic Surgery, 2007